Catherine Guy, Outgoing Managing Partner and Feargal Brennan, Managing Partner, ByrneWallace (Photo: Chris Bellew/Fennell Photography)
Business & Finance highlights notable new appointments at ByrneWallace, Glanbia, Spark Foundry and OncoMark.
Feargal Brennan, Managing Partner
ByrneWallace has announced Feargal Brennan as Managing Partner. He takes over the role from Catherine Guy, who completed a six-year term.
Brennan is a senior corporate lawyer and joined ByrneWallace in 2000 and has been head of the firm’s corporate division since 2011.
He was over two decades’ experience in advising Irish and international businesses across a wide range of corporate matters. His expertise lies in mergers and acquisitions, private equity and venture capital trasnactions.
Brennan commented on his appointment, saying:
This is an exciting time for ByrneWallace. Under Catherine’s leadership we have greatly enhanced the depth and strength of our service lines. As a leading business law firm, we are ideally positioned to meet the increasingly complex needs of our clients, both private and public, Irish and international.
Outgoing Managing Partner Catherine Guy added:
Feargal has made a considerable contribution to the development of the firm, and in particular to growing and developing our corporate team and corporate services. Under his leadership, we have firmly established ByrneWallace as one of Ireland’s leading corporate law practices.
She continued: “On behalf of the partners and the team in ByrneWallace, we wish Feargal every success as Managing Partner. I am confident that under Feargal’s leadership, ByrneWallace will continue to place our clients at the very centre of all that we do, providing consistently excellent legal services in a rapidly-changing and dynamic environment.”
Martin Keane, Group Chairman
Patrick Murphy, Vice-Chairman
Martin Keane has been announced as Glanbia’s new Group Chairman, succeeding Henry Corbally.
Patrick Murphy has assumed Keane’s role as Vice-Chairman
Martin Keane said:
I am very pleased to be appointed to serve as Group Chairman of Glanbia. I will continue to build on the work of all those who have had the vision to make Glanbia the global nutrition group it is today and to help steer the business through its next phase of growth and development. I look forward to working with the board, the executive team and employees to ensure that the organisation continues to deliver on our strategic ambitions for all our shareholders and stakeholders. On behalf of the entire Glanbia organisation, I would also like to thank my predecessor, Henry Corbally, for his leadership and commitment as Chairman for the last three years.
In addition, Jer Doheny has been appointed as a Non-Executive Director and Tom Grant and Patsy Ahern have retired as Non-Executive Directors of Glanbia plc.
Helen O’Rourke, Deputy Managing Director
Spark Foundry appointed Helen O’Rourke as Deputy Managing Director.
O’Rourke joined Spark Foundry 12 years ago and was appointed to the board in 2014. She is an IAPI representative on both the Research and the Technical Committees of the JLNR and teaches a number of courses in Core Learning.
Sandra Alvarez, Managing Director of Spark Foundry, says:
Helen is undoubtedly one of the most talented practitioners in our market. Her commitment to making our industry better is remarkable and she constantly raises the bar for the standard of the work we do. Helen is an integral part of the Spark Foundry team and I’m really looking forward to working alongside her to bring the agency to even higher levels.
Professor John Crown, Chief Medical Officer
Professor John Crown has been appointed Chief Medical Officer at OncoMark.
Professor Crown is a consultant medical oncologist at St Vincent’s University Hospital, Dublin and is a thought leader who has published much research in clinical and translational breast cancer research.
Professor John Crown MD, MBA, a consultant medical oncologist at St. Vincent’s University Hospital, Dublin, is an oncology thought leader who has published extensively in clinical and translational breast cancer research.
Commenting on the appointment Des O’Leary, CEO, OncoMark, said:
I am delighted to welcome such a renowned clinical oncologist and thought leader to the company. Through his extensive clinical experience and deep knowledge of the clinical utility of biomarker tests in oncology, Professor Crown will play a vital role as we launch the OncoMasTR test in global markets.
Professor John Crown said:
I am delighted to have been appointed OncoMark’s CMO. I am very excited about the potential of the company’s technology platform and believe the OncoMasTR breast cancer test comprehensively addresses barriers to adoption of prognostic tests. It delivers on the promise of personalised treatment choices in a cost effective manner and will bring the benefits of precise molecular prognostication to women who currently cannot access it.